Probiotics for Visceral Fat: Evidence and Tips

Probiotics for visceral fat is a growing area of research interest, as scientists explore how gut microbiome composition may influence where and how the body stores fat. Visceral fat, the deep abdominal fat surrounding internal organs, is strongly linked to type 2 diabetes, cardiovascular disease and metabolic dysfunction. Unlike subcutaneous fat, it cannot be seen or pinched, yet it poses significant health risks. This article examines what the current evidence says about whether probiotics can help reduce visceral fat, which strains have been studied, how long supplementation may need to continue, and what lifestyle measures offer the strongest supporting evidence.

What is visceral fat and why does it matter for your health?

Visceral fat is metabolically active fat stored deep in the abdominal cavity that releases inflammatory cytokines and free fatty acids, significantly increasing the risk of type 2 diabetes, cardiovascular disease and metabolic liver disease.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it carries greater health risks than subcutaneous fat stored just beneath the skin. Unlike the fat you can pinch at the waist, visceral fat is not visible from the outside, yet it is strongly associated with an increased risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and certain cancers.^[7][8]

Visceral fat is metabolically active in a way that makes it particularly harmful. It releases inflammatory cytokines and free fatty acids directly into the portal circulation, which can impair insulin signalling and promote systemic inflammation.^[7][8] This is why two people with a similar body weight can have very different cardiometabolic risk profiles depending on where their fat is distributed.

In clinical practice, waist circumference is a practical proxy for visceral fat burden. UK guidance indicates that a waist circumference above 88 cm (35 inches) in women and above 102 cm (40 inches) in men is associated with substantially increased health risk.^[2] However, these thresholds are not universal: for people of South Asian, Chinese, Japanese and other Asian backgrounds, risk increases at lower waist circumferences, and lower thresholds apply.^[2][3] Your GP or practice nurse can advise on the appropriate threshold for you.

Alongside waist circumference, UK guidance also recommends using the waist-to-height ratio as a practical screening measure. A waist-to-height ratio below 0.5 is generally considered a healthy target for adults. This measure can be useful because it accounts for differences in height and may better reflect abdominal fat distribution across different body types.

Imaging techniques such as MRI or CT scanning can quantify visceral fat more precisely, but they are not routinely used in primary care for adiposity assessment. Understanding what drives visceral fat accumulation, including diet, physical inactivity, poor sleep and gut microbiome composition, is the first step towards addressing it effectively. Research suggests an association between gut microbiome composition and metabolic health, though the direction and magnitude of this relationship in humans is still being established.

Can probiotics actually help reduce visceral fat?

Probiotics can produce modest, statistically significant reductions in visceral fat in some people, but effect sizes are small and they are best used as one component of a broader lifestyle strategy rather than a standalone treatment.

Probiotics can modestly reduce visceral fat in some individuals, but the evidence is preliminary and the effect sizes observed in clinical trials are generally small rather than transformative. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host, as defined by the World Health Organisation and the Food and Agriculture Organisation of the United Nations.^[1] Their potential role in body composition has attracted growing research interest, largely because of the observed association between gut microbiome composition and metabolic health.

The proposed mechanisms are plausible but remain under investigation, and much of the supporting evidence comes from preclinical studies or small human trials. Certain probiotic strains may reduce intestinal permeability, potentially lowering the translocation of bacterial lipopolysaccharides into the bloodstream and thereby dampening the low-grade inflammation thought to promote visceral fat accumulation. Other strains appear to influence the production of short-chain fatty acids, which may affect appetite-regulating hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY. Some research also suggests that specific strains may modulate bile acid metabolism, which in turn could affect fat absorption and energy expenditure. These mechanisms are hypothesised on the basis of available evidence and have not all been confirmed in large, well-controlled human trials.

A 2019 meta-analysis published in Obesity Reviews, examining data from multiple randomised controlled trials, found that probiotic supplementation was associated with statistically significant but modest reductions in body weight, body mass index and waist circumference compared with placebo. The authors noted considerable heterogeneity between studies in terms of strains used, doses, duration and participant characteristics. It is therefore not yet possible to make a blanket recommendation that probiotics reliably reduce visceral fat for all people. They are best understood as one component of a broader lifestyle approach rather than a standalone intervention.

Who should exercise caution or avoid probiotics: Probiotics are generally well tolerated in healthy adults, but they are not appropriate for everyone. People who are severely immunocompromised, critically ill, or who have a central venous catheter in place should avoid probiotic supplements unless specifically advised otherwise by a clinician. Probiotics should also be avoided during severe acute pancreatitis. If you are pregnant or breastfeeding, seek advice from your GP or midwife before starting a probiotic supplement. Common mild side effects include bloating, flatulence and loose stools, particularly in the first few days of use. If you experience any unexpected or persistent symptoms after starting a probiotic, stop taking it and seek medical advice. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Which probiotic strains have the most evidence behind them?

Lactobacillus gasseri SBT2055, Lactobacillus rhamnosus CGMCC1.3724 and Bifidobacterium lactis strains have the most clinical trial evidence, though effects are strain-specific and cannot be generalised across products.

The strains with the most consistent evidence for an effect on body composition and visceral fat belong primarily to the Lactobacillus and Bifidobacterium genera, with Lactobacillus gasseri, Lactobacillus rhamnosus and Bifidobacterium lactis attracting the most research attention. It is important to note that probiotic effects are highly strain-specific: evidence for one strain cannot be extrapolated to another, even within the same species, and findings from one dose or formulation may not apply to a different product.

Lactobacillus gasseri SBT2055 has been studied in several randomised controlled trials, including work by Kadooka and colleagues. One 12-week trial found that participants consuming fermented milk containing this strain experienced a statistically significant reduction in visceral fat area compared with a placebo group, as measured by CT scanning. Lactobacillus rhamnosus CGMCC1.3724 has shown effects on weight management, particularly in women, in trials by Sanchez and colleagues, though findings have been less consistent in men. Bifidobacterium lactis strains have been associated with improvements in metabolic markers including fasting glucose and waist circumference in some trials, though the evidence base varies by specific strain and study population.

Multi-strain formulations are also under investigation, with some evidence suggesting that combinations may produce additive effects on gut microbiome diversity and metabolic outcomes. However, the research landscape is complicated by variability in:

• Probiotic dose (measured in colony-forming units, or CFUs)

• Delivery vehicle (capsule, fermented food, drink)

• Baseline gut microbiome composition of participants

• Dietary background during the trial

In the UK, probiotics are regulated as food supplements rather than licensed medicines. This means they are not subject to the same pre-market efficacy and safety evaluation as pharmaceutical products, and manufacturers cannot make authorised medicinal claims on their labelling. When choosing a product, look for one that clearly states the full strain name (genus, species and strain code), the CFU count guaranteed at end of shelf life (not just at manufacture), and that has been produced to recognised quality standards. A pharmacist can help identify reputable products available in the UK.

How long do you need to take probiotics before seeing results?

Most trials reporting measurable changes in visceral fat used 8 to 12 weeks of supplementation, so at least two to three months of consistent use is likely needed before any effect on body composition becomes apparent.

Most clinical trials that have reported measurable changes in visceral fat or waist circumference have used supplementation periods of 8 to 12 weeks, suggesting that at least two to three months of consistent use is likely necessary before any meaningful effect on body composition becomes apparent. Shorter durations of two to four weeks may be sufficient to alter gut microbiome composition in some studies, but changes in body fat distribution take considerably longer to manifest.

The timeline also depends on the individual. Factors such as baseline gut microbiome diversity, diet quality, physical activity level and the specific probiotic strain and dose all influence how quickly, or whether, a response occurs. Some people may notice improvements in digestive comfort, bloating or bowel regularity within the first few weeks, but these gastrointestinal changes are distinct from any effect on visceral fat.

It is also worth noting that the benefits of probiotics on gut microbiome composition appear to be transient in many people. Studies using faecal microbiome analysis have shown that colonisation by supplemented strains often diminishes within weeks of stopping supplementation. This suggests that ongoing use, combined with a diet rich in prebiotic fibre (found in foods such as oats, leeks, garlic and chicory root) to support the growth of beneficial bacteria, may be necessary to sustain any metabolic benefit.

If you have been taking a probiotic consistently for three months without any noticeable change in your waist measurement or general metabolic wellbeing, it is reasonable to discuss this with your GP, who can assess whether further investigation or a different approach is warranted.

Probiotics are not suitable for everyone. People who are severely immunocompromised, critically ill, or who have a central venous catheter should not take probiotic supplements without specific clinical advice. They should also be avoided in severe acute pancreatitis. If you are pregnant or breastfeeding, speak to your GP or midwife before starting any supplement. Stop taking a probiotic and seek medical advice if you develop unexpected or persistent symptoms.

What else can you do alongside probiotics to tackle visceral fat?

Aerobic exercise, resistance training, a Mediterranean-style diet and 7 to 9 hours of quality sleep per night all have stronger and more consistent evidence for reducing visceral fat than probiotics alone.

Probiotics are most effective when used as part of a comprehensive lifestyle strategy, and the evidence for dietary change, physical activity and sleep improvement in reducing visceral fat is considerably stronger and more consistent than the evidence for probiotics alone. A Mediterranean-style diet, characterised by high intake of vegetables, legumes, wholegrains, oily fish and olive oil, has been associated with reduced visceral fat in multiple observational studies and several randomised trials.

Regular physical activity is one of the most effective interventions for visceral fat specifically. Both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training have been shown to reduce visceral fat independently of changes in total body weight. The UK Chief Medical Officers' Physical Activity Guidelines recommend that adults aim for at least 150 minutes of moderate-intensity activity per week, with additional benefit from higher volumes.^[14][15] These guidelines are also reflected in NHS advice on physical activity for adults.

Sleep quality and duration are increasingly recognised as important determinants of visceral fat accumulation. Chronic sleep restriction is associated with elevated cortisol and ghrelin levels, which promote fat storage in the abdominal region. Aiming for 7 to 9 hours of good-quality sleep per night is a practical and evidence-supported target, in line with NHS guidance on sleep health.

For individuals with a BMI of 30 or above, or 27.5 or above with weight-related comorbidities, clinically supervised weight management may be appropriate. Eligibility for specific pharmacological treatments on the NHS is determined by NICE technology appraisals and local Integrated Care Board (ICB) commissioning decisions, and thresholds may differ depending on the medicine or service in question. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of options may be considered based on individual clinical need. Any prescription medicine would only be provided where clinically appropriate following a consultation. Regardless of the approach taken, reducing visceral fat is a gradual process that benefits from sustained, consistent effort across multiple lifestyle domains.

Scientific References

1. Probiotics.
2. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
3. Overweight and obesity management (NG246): Appendix A1 – Summary of evidence from surveillance.
4. Overweight and obesity management (NG246): A guide for prescribing medicines to manage overweight and obesity.
5. Calculate your waist to height ratio.
6. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value.
7. Visceral fat and metabolic inflammation: the portal theory revisited.
8. Visceral fat and insulin resistance – what we know?.
9. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomised controlled trial.
10. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.
11. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women.
12. Effects of a diet-based weight-reducing program with probiotic supplementation on satiety efficiency, eating behaviour traits, and psychosocial behaviours in obese individuals.
13. The potential role of probiotics in controlling overweight/obesity and associated metabolic parameters in adults: a systematic review and meta-analysis.
14. Physical activity guidelines: UK Chief Medical Officers' report.
15. Physical activity guidelines for adults aged 19 to 64.
16. Nutrition legislation information sheet.
17. Overweight and obesity in adults.

Frequently Asked Questions